



PRESS RELEASE

May 15th, 2025

G7 CANCER: A NEW MOMENTUM FOR AN AMBITIOUS INTERNATIONAL INITIATIVE IN THE FIGHT AGAINST CANCER

On May 5, the French National Cancer Institute (INCa) and its international partners held the 3rd Strategic Committee of the G7 Cancer. Launched in May 2023 at the initiative of INCa, the G7 Cancer brings together seven founding members from some of the world's most advanced countries in cancer control, along with the International Agency for Research on Cancer (IARC), which joined the group as an observer in 2024. The aim of this initiative is to strengthen international coordination and accelerate the fight against cancer.

During the Committee meeting, held at INCa headquarters in Boulogne, all international partners discussed key topics including: a review of the first two years of activity focused on four jointly defined priority areas, perspectives for future joint projects, the financial sustainability of the initiative, and the organization of the rotating presidency, which has so far been held by INCa.

The next major milestone will be the upcoming conference titled "Poor Prognosis Cancers: From Resignation to Revolution", to be held in Paris on June 26, 2025.



(From left to right) Dr. Tomohiro Matsuda (NCC), Nicolas Scotté (INCa), Marie-Charlotte Henrion (INCa), Marilyn Penn (Cancer Australia), Dr. Fei-Fei Liu (CIHR), Thomas Dubois (INCa), Fiona Chennells (CRUK), Prof. Norbert Ibrah (INCa), Prof. Michael Baumann (DKFZ), Dr. Catherine Elliott (CRUK), Prof. Bruno Quesnel (INCa), Prof. Dorothy Keefe (Cancer Australia), Prof. Claude Linassier (INCa), Clément Chauvet (IARC), Dr. Claudia Mayer (DKFZ), Dr. Jérôme Viguier (INCa), Dr. Wakako Toga (NCC), Prof. Hiroyuki Mano (NCC).

G7 Cancer: An assessment that reflects the strong commitment of its experts

At its inaugural meeting in May 2023, the G7 Cancer identified four priority themes, each addressed by a dedicated working group:

1. International data sharing, using pediatric cancers as a model
2. Cancers with poor prognosis
3. Cancer-related inequalities
4. Prevention (precancerous conditions, screening programs, early detection)

The Strategic Committee reviewed the progress made by each working group during the first two years of collaboration. Recent months have been marked by strong momentum, driven by the commitment of the involved experts. The working groups have successfully created new spaces for exchange, reflection, and scientific output through webinars, publications, and the organization of events.

Following the **Paris Conference for an International Childhood Cancer Data Partnership** in November 2023 and [the subsequent report](#), the first working group (co-led by the NCI and INCa) published a scientific article in January 2025 entitled "[Making the Case for an International Childhood Cancer Data Partnership](#)" in the Journal of the National Cancer Institute.

The second working group is finalizing a scientific article on definitions and epidemiological characteristics of poor prognosis cancers in G7 Cancer countries. Co-led by the NCC and INCa, this group is also organizing a **scientific conference on June 26 in Paris**, marking an important milestone in its ongoing work.

The third working group (co-led by CIHR and Cancer Australia) is preparing a report on cancer-related inequalities. The report will identify affected populations, how G7 Cancer countries are addressing this issue through public policy, and explore opportunities for collaboration to reduce these disparities.

The fourth working group on prevention (co-led by NCI, DKFZ, and CRUK) has organized two webinars—one on lung cancer screening in G7 countries, and another on precision prevention, an emerging research topic. [Watch the replays of both webinars.](#)

The growing recognition of the G7 Cancer by international institutions, and the relevance of its chosen themes, confirm the legitimacy and impact of this initiative. More than ever, G7 Cancer stands as a powerful tool to sustainably enhance international cooperation in the fight against cancer.

Uniting to overcome poor prognosis cancers: A Conference in Paris on June 26

Led by the NCC and INCa, the second working group on poor prognosis cancers is organizing a **conference on June 26 in Paris**. This event will bring together leading international experts and will mark the **official launch of a multinational initiative** dedicated to improving care for poor prognosis tumors.

The discussions—gathering experts, researchers, policymakers, and healthcare professionals—will aim to **share knowledge and develop strategies** to enhance care for patients with poor prognosis cancers. The focus will be on **digestive cancers**.

[View the program and register for the conference.](#)

The G7 organizations:

- Australia – Cancer Australia
- Canada - Canadian Institute of Health Research (CIHR)
- France – National Cancer Institute (INCa)
- Germany – German Cancer Research Center (DKFZ)
- Japan - National Cancer Center (NCC)
- United Kingdom - Cancer Research UK (CRUK)
- United States - Department of Health and Human Services, National Cancer Institute (NCI)
- In 2024 the International Agency for Research on Cancer (IARC) joined the G7 Cancer as an observer



[Check out all the actions and events on G7 Cancer here](#)

About French National Cancer Institute

The French National Cancer Institute (INCa) was established under the French Public Health Act of August 9, 2004, as the State health and science agency specialised in cancer control. It includes State representatives, charities, health insurance funds, hospital federations and research organizations and operates under the dual auspices of the French Ministry of Health and Solidarities and the French Ministry of Higher Education, Research and Innovation. It provides an integrated approach encompassing all cancer-control aspects (health, scientific, social and economic) and intervention areas (prevention, screening, care, research) to benefit patients and their relatives. To catalyse progress, the INCa acts as an interface with patients, their friends and families, the healthcare system users, the general public, healthcare professionals, researchers, experts and decision-makers. The Institute ensures the implementation of the ten-year cancer control strategy 2021-2030 <http://www.cancer.fr/> X

Press contacts

For media enquiries please contact the PR Manager on 00(33) 1 44 10 14 44/00 (33) 6 20 72 11 25 or presseinca@institutcancer.fr